If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> DERMATOLOGY<br /> EMJ Dermatol. 2019 Suppl 10 • europeanmedical-journal.com<br /> INSIDE<br /> IL-23 Inhibition: From<br /> Pathophysiological Jungle<br /> to Clinical Clearance<br /> Latest Highlights from<br /> Guselkumab in Psoriasis<br /> from EADV 2019<br /> IL-23 Inhibition: From Pathophysiological<br /> Jungle to Clinical Clearance<br /> This symposium took place on 10th October 2019, as part of the 28th<br /> Annual European Academy of Dermatology and<br /> Venereology (EADV) Congress in Madrid, Spain<br /> Chairpeople: Kristian Reich,1,2 Richard Warren3<br /> Speakers: Kristian Reich,1,2 Richard Warren,3 Brian Kirby4<br /> 1. University Clinic Hamburg-Eppendorf, Skinflammation®, Hamburg, Germany<br /> 2. Dermatologikum Berlin, Berlin, Germany<br /> 3. University of Manchester and Salford Royal NHS Foundation Trust, Manchester, UK<br /> 4. St Vincent’s University Hospital, Dublin,<a title="EMJ Dermatol. 2019 Suppl 10 page 1" href="http://viewer.zmags.com/publication/685622a2?page=1"> DERMATOLOGY EMJ Dermatol. 2019 Suppl 10 • europea</a> <a title="EMJ Dermatol. 2019 Suppl 10 page 2" href="http://viewer.zmags.com/publication/685622a2?page=2"> IL-23 Inhibition: From Pathophysiological </a> <a title="EMJ Dermatol. 2019 Suppl 10 page 3" href="http://viewer.zmags.com/publication/685622a2?page=3"> arthritis (PsA) disease domains, and these differ</a> <a title="EMJ Dermatol. 2019 Suppl 10 page 4" href="http://viewer.zmags.com/publication/685622a2?page=4"> TNF-α IL-17A/F IL-23 IL-17C/E Figure 1: </a> <a title="EMJ Dermatol. 2019 Suppl 10 page 5" href="http://viewer.zmags.com/publication/685622a2?page=5"> EMA Guselkumab November 2017 2017 </a> <a title="EMJ Dermatol. 2019 Suppl 10 page 6" href="http://viewer.zmags.com/publication/685622a2?page=6"> But how does the efficacy of IL-23 inhibitors com</a> <a title="EMJ Dermatol. 2019 Suppl 10 page 7" href="http://viewer.zmags.com/publication/685622a2?page=7"> Therefore, dermatologists play a key role in the </a> <a title="EMJ Dermatol. 2019 Suppl 10 page 8" href="http://viewer.zmags.com/publication/685622a2?page=8"> psoriasis. J Allergy Clin Immunol. 2017;139(3):92</a> <a title="EMJ Dermatol. 2019 Suppl 10 page 9" href="http://viewer.zmags.com/publication/685622a2?page=9"> arthritis. Clin Cosmet Investig Dermatol. 2015;8:</a> <a title="EMJ Dermatol. 2019 Suppl 10 page 10" href="http://viewer.zmags.com/publication/685622a2?page=10"> Latest Highlights from Guselkumab in Psoriasis </a> <a title="EMJ Dermatol. 2019 Suppl 10 page 11" href="http://viewer.zmags.com/publication/685622a2?page=11"> clinical trial programme in psoriasis, as present</a> <a title="EMJ Dermatol. 2019 Suppl 10 page 12" href="http://viewer.zmags.com/publication/685622a2?page=12"> scores at Week 48 compared with those who receive</a> <a title="EMJ Dermatol. 2019 Suppl 10 page 13" href="http://viewer.zmags.com/publication/685622a2?page=13"> achieved IGA 0 regardless of psoriasis treatment </a> <a title="EMJ Dermatol. 2019 Suppl 10 page 14" href="http://viewer.zmags.com/publication/685622a2?page=14"> Differential Impact of IL-23 vs IL-1</a> <a title="EMJ Dermatol. 2019 Suppl 10 page 15" href="http://viewer.zmags.com/publication/685622a2?page=15"> with guselkumab, while the equivalent cellular po</a> <a title="EMJ Dermatol. 2019 Suppl 10 page 16" href="http://viewer.zmags.com/publication/685622a2?page=16"> and tolerability profile of this IL-23 inhib</a>